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Summary. The i.p. delivery of murine monoclonal anti- 
body was compared with i.v. delivery in normal mice and 
rats, in normal nude mice and in those with i.p. human 
ovarian carcinoma xenografts. In normal rats, all classes 
of antibodies and antibody fragments evaluated were 
cleared from the peritoneal cavity at comparable rates. 
The regional delivery (Rd 1) advantage to the peritoneal 
cavity following i.p. delivery was thus most dependent on 
the rate of clearance of the antibody or fragment from the 
blood stream. Determining the exact i.p. delivery advan- 
tage was problematic due to the difficulty in reliably ob- 
taining peritoneal fluid later than 9-10 h after i.p. injection 
in normal animals. During the first 9 h following i.p. injec- 
tion, the Rd(0-9/0-9) was, for a murine IgG2ak Fab > 
F(ab')2 > IgG (at 13.6 > l0 > 7.9). Two murine IgMs 
evaluated differed in Rd(0-9) at 27.1 and 9.2 respectively. 
When blood levels were extrapolated to infinity, these Rd 
(0-9/oo) values were considerably lower with the Fab hav- 
ing the highest Rd at 4.67. The i.p. Rd advantage was al- 
most solely due to the i.p. antibody levels seen in the first 
24 h after injection, as after that time, blood levels become 
comparable to those seen following i.v. injection. Normal 
tissues obtained at sacrifice 5-7 days after i.p. injection. 
Normal tissues obtained at sacrifice 5-7 days after i.p. or 
i.v. injection in rats showed comparable levels of radioan- 
tibody activity, whether the injection was i.p. or i.v. (except 
for higher diaphragmatic levels following i.p. delivery). In 
nude mice with i.p. human-derived ovarian tumors, intact 
IgG clearance from the peritoneal cavity to the blood was 
considerably slower than in normal animals, and early i.p. 
tumor uptake of specific antibody was significantly higher 
than that following i.v. antibody delivery. With higher ear- 
ly tumor uptake and lower systemic exposure, early 
tumor/nontumor  ratios were significantly greater than 
Rd is area under the curve (AUC) for peritoneal fluid activity / 
AUC for blood radioactivity. Rd (0-9/0-9) is the Rd measured 
from 0 to 9 h for both peritoneal fluid and blood. Rd (0-9/0o) is 
the conservative estimate of Rd with i.p. fluid AUC measured to 
9 h, with blood levels extrapolated to infinity. Rd 2 is Rd/(AUC 
i.p. fluid (0-9)/AUC blood (0-9)) after i.v. injection. 
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those for i.v. delivery, though not beyond 48 h after i.p. in- 
jection. This study demonstrates the pharmacokinetic ra- 
tionale for i.p. monoclonal antibody delivery, especially 
for agents cleared rapidly from the blood, such as anti- 
body  fragments. In addition, definite i.p. delivery benefit 
for antibody specific to i.p. tumors in the i.p. ovarian can- 
cer system was shown soon after injection. These data re- 
garding i.p. antibody delivery should be useful in rational- 
ly planning diagnostic and therapeutic studies involving 
the i.p. delivery of unmodified and immunoconjugated 
monoclonal antibodies. 
Introduction 
Regional delivery (Rd) of chemotherapeutic agents to the 
peritoneal and other cavities has been used in the treat- 
ment of malignant diseases restricted to such spaces, such 
as ovarian carcinoma [7, 11, 20]. With the development of 
monoclonal antibodies reactive with ovarian carcinoma, 
some of which when radiolabeled are capable of immuno- 
imaging such tumors, the i.v. and more recently the i.p. 
routes of antibody delivery to such regionally limited dis- 
eases have been explored [2, 4, 9, 10, 25, 27]. While there 
has been preliminary clinical utilization of the i.p. delivery 
route for ovarian cancer therapy in humans, relatively 
little is known about the clearance rate of monoclonal an- 
tibodies from the peritoneal cavity. 
It is clear that higher concentrations of radiolabeled 
antibodies present in a given region will result in higher 
binding to target antigens in that region, due to binding ki- 
netic considerations [14]. We have recently shown for radio- 
iodinated intact murine IgG2ak, that increased antibody 
concentration compared to blood levels exists in the peri- 
toneal cavity of rats following i.p. antibody administration 
[21, 24]. We also showed that this i.p. delivery advantage 
could be further enhanced by accelerating the clearance of 
the intact IgG from the blood stream using a systemically 
administered polyclonal anti-mouse antibody [21]. 
Through such a manipulation, the Rd advantage following 
i.p. administration could be increased by approximately 
50% in the first 10 h after injection. 
Since quite marked differences exist among the blood 
clearance rates and tumor imaging properties of intact 
monoclonal antibodies and monoclonal antibody frag- 
ments following intravascular delivery, it is possible that 
similar differences in clearance may exist for i.p. delivered 
monoclonal antibodies [3, 5, 23] and that there might be 
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large differences in the Rd advantage when given i.p. The 
present study was conducted to determine the extent of the 
Rd advantage to the peritoneal space for monoclonal an- 
tibodies, as well as the influence of antibody class and 
fragmentation on the delivery advantage. This report also 
evaluates the influence of i.p. human tumor xenografts on 
antibody clearance from the peritoneal space and ex- 
amines the extent of localization improvement of specific 
antibody to i.p. human ovarian carcinoma xenografts fol- 
lowing i.p. versus i.v. delivery. 
Material and methods 
Monoclonal antibodies. The 225.28S is an IgG2ak murine 
monoclonal antibody reactive with the high molecular 
weight antigen of melanoma [33]. Hybridoma cells produc- 
ing this reagent were grown in pristane-primed (Aldrich) 
Balb/c mice as ascites, and then purified by staphylococ- 
cal protein A chromatography [8]. Then 225.28S F(ab')2 
fragments were prepared by 2% pepsin digestion in pH 4.2 
acetate buffer, with subsequent purification by dialysis 
and on a staphylococcal protein A column [8, 15, 23]. The 
225.28S Fab fragment was prepared by 2% papain diges- 
tion with purification of the Fab from the Fc on a staphy- 
lococcal protein A column, followed by additional purifi- 
cation using TSK sizing HPLC [16]. FTI66 is an IgM 
of murine origin, which was purified by DEAE chroma- 
tography from mouse ascites (Liebert et al, unpublished 
data) [32]. UPC-10 is an IgG2a monoclonal antibody pur- 
chased in purified form (Bionetics Research, Charleston, 
SC). BA-1 is a murine IgM, (generously provided by Hy- 
britech, LaJolla, Calif.) [1], reactive with human B-cells 
which was purified from carrier human albumin protein 
using TSK sizing HPLC. 5G6.4 is an IgG2a murine mono- 
clonal antibody with preferential reactivity with ovarian 
and other epithelial cancers [27]. It was purified from as- 
cites by staphylococcal protein A chromatography. None 
of these murine antibodies are known to cross-react with 
normal mouse or rat tissues. The molecular weight and pu- 
rity of these reagents was verified on 7.5% sodium dodecyl 
sulfate (SDS) polyacrylamide gels with and without 2-mer- 
captoethanol [12]. 
Radiolabeling. All labelings were conducted using 131I or 
125I (New England Nuclear, Boston, Mass.), by the Iodo- 
bead or Iodogen method (Pierce Chemical, Rockford, Ill.) 
[13]. In general, 1 mCi was used to label 50--100 p~g of an- 
tibody protein, and free iodine was removed from the mix- 
ture by Biogel P-60 sizing chromatography (Bio-Rad La- 
boratories, Richmond, Calif.). Iodine incorporation was in 
the 30% to 70% range. Freedom from iodine contamination 
was demonstrated by thin layer chromatography with 50% 
ethyl acetate and 50% ethanol [26]. In tumor-specific anti- 
body studies the proportion of iodinated 5G6.4 or iodinat- 
ed UPC-10 binding to 1-2 Xl06 HTB77 antigen-positive 
tumor cells in a 1-h incubation was also assessed in a di- 
rect cell binding assay [26]. 
Animal studies. Adult, approximately 180-250 g, female 
Sprague-Dawley rats were sedated with pentobarbital giv- 
en i.p. (40 mg/kg). The animals were then placed in a su- 
pine position and a portion of their ventral abdomen 
shaved. The skin over the midline of the abdomen was 
opened for about 1 cm, with a portion of parietal perito- 
neum exposed. The i.p. injections of antibody were per- 
formed with a 27-gauge needle attached to a 20 ml syringe 
under direct visualization. Preliminary studies using India 
ink in saline demonstrated that this approach resulted in 
i.p. fluid delivery without significant leakage. Peritoneal 
fluid was subsequently sampled (50-100 gl aliquots) us- 
ing a tuberculin syringe fitted with a 28-gauge needle (un- 
der direct visualization). The i.v. injections were carried 
out by direct cannulation of the femoral vein with a 
28-gauge needle after an incision had been made in the 
skin overlying the vein. 
In studies using i.p. tumor-bearing nude mice (approxi- 
mately 8-12-week-old tumors), the 1251 5G6.4 antibody was 
given either i. p. or i.v. with animal sacrifice 4, 24, 48, or 
120 h later. Uptake in i.p. tumor foci (HTB77 IP3 line of 
human ovarian cancer) [31] and blood was compared be- 
tween delivery routes (i.p. or i.v.). In addition, a dual-label 
experiment comparing simultaneously i.p. administered 
5G6.4 and UPC-10 was conducted to confirm the specifici- 
ty of tumor uptake. The rate of i.p. clearance of the 
nonspecific IgG2ak, UPC-10, was also studied in normal 
nude mice, nude mice with i.p. ovarian tumors, and in 
healthy BALB/c mice without such tumors. Gamma imag- 
ing following i.p. administration was also performed using 
a large field of view gamma camera equipped with a high- 
energy parallel hole or a pinhole collimator in selected in- 
stances. The images were digitally recorded in a dedicated 
computer for subsequent display and analysis. All images 
were performed using a 20% window centered at 364 KeV. 
Time course experiments. In experiments evaluating i.p. an- 
tibody delivery in normal rats, groups of 3-7 adult female 
rats were injected i.p. with approximately 5-20 p.Ci of la- 
beled antibody (0.2-1 p~g) in a total volume of 20 ml of 
warm, 0.01 M phophate-buffered saline, pH 7.0. The 20 ml 
volume was chosen, as some studies have suggested that a 
large i.p. fluid volume is useful in assuring uniform i.p. 
drug distribution [18]. Sequential blood samplings from 
the tail vein, and peritoneal fluid samplings by direct re- 
moval of peritoneal fluid using a 28-gauge needle attached 
to a syringe were accomplished, with weighing and gamma 
counting of peritoneal fluid and blood. Peritoneal fluid 
could not commonly be obtained beyond 9-15 h after in- 
jection, due to resorption of fluid, particularly in the non- 
tumor-bearing animals. In the time course experiments in 
rats, the animals were kept sedated by occasional (every 
2-6 h) small (=  100 p~L), i.p. boosts of pentobarbital during 
the first 9-10 h of the study. The animals were then al- 
lowed to recover, with additional blood and (when possi- 
ble) peritoneal fluid samples obtained up to 1-7 days after 
injection, during brief sedation with ether. Animals were 
sacrificed at the conclusion of the study when normal or- 
gans were weighed and counted. 
The experiments evaluating i.v. antibody delivery were 
very similar, with the exception that the radiolabeled anti- 
body was given by femoral vein injection, while 20 ml of 
warm phosphate-buffered saline, devoid of antibody, was 
given i.p. Samplings of blood and peritoneal fluid, as well 
as normal organs at sacrifice, were performed in an identi- 
cal fashion. In several experiments, a dual-label approach 
was used [17]. 
These experiments were performed for all antibodies 
and fragments (except that the UPC-10 (data previously 
reported) [21] and BA-1 were studied only following i.p. 
189 
administration and then to only 24 h after injection). The 
data were corrected for decay, and plotted as a time activi- 
ty curve for the peritoneal cavity, and the blood. The Rd 
advantage was calculated for the first 9 h of the study (and 
to infinity where data were available) by measuring the 
area under the curve (AUC) for i.p. antibody delivery to 
the peritoneal cavity and the blood as follows [18]: 
Rd = AUC peritoneal cavity 
AUC blood 
Due to difficulty in computer fitting the terminal portion 
of the i.p. activity curves and due to difficulty in obtaining 
fluid reliably beyond 9-10 h in nontumor-bearing animals, 
a very conservative estimate of Rd to infinity (Rd 0-9/00) 
was also made by dividing the measured i.p. antibody 
AUC to 9 h by the blood AUC to infinity. An Rd 0-9/0-9 
was also calculated, comparing the AUC i.p. to 9 h to the 
AUC 0-9 h for blood. A log-linear trapezoidal best fit 
computer program was used to fit curves and estimate 
AUCs. When i.p. fluid could be obtained up to 15 h, a Rd 
0-15/0-15 was also determined. Another estimate of re- 
gional delivery advantage, Rd 2 was determined as follows 
[7]: 
Rd 2 (0-9) = Rd ( 0 - 9 / 0 - 9 )  
AUC peritoneal cavity (0-9) with i.v. administration 
AUC blood (0-9) 
Tissue distributions. Tissue biodistributions of the radio- 
labeled antibodies and fragments following i.v. and i.p. de- 
livery routes were determined at sacrifice 4-7 days after 
antibody injection in rats, and at times ranging from 4 h to 5 
days in nude mice with tumors and BALB/c mice, when 
major organs and/or  tumors were removed, weighed, blot- 
ted, and counted with percent kilogram dose per gram de- 
termined using standard tissue handling techniques. 
Absorption rate constant determination. A compartmental 
analysis was performed on the individual i.p. concentra- 
tion time profiles using the program AUTOAN [19]. In 
those instances in which a model could be used to fit the 
data, the absorption rate constant was calculated for the 
antibodies administered via i.p. injection. In most cases, a 
one compartment model with first order absorption was 
the model of choice. 
Statistical analysis. Differences among groups of Rds were 
assessed by analysis of variance or by the Fishers protect- 
ed least square difference method. A computerized best-fit 
graphic system allowing for multiexponential curve fitting 
was used to determine segmental terminal phase tl/2s. One- 
way analysis of variance, the Scheffe F-test and Dunnett 
t-tests were used in the analysis of the absorption rate con- 
stant data. 
Results 
Effects of class and fragmentation in normal rats 
Clearance curves for the varying antibodies and fragments 
from the blood of healthy rats following i.v. injection are 
shown in Fig. 1. Note that the terminal phase tlA of blood 
clearance of intact IgG 225.28S (52.3 h _ 6.09 standard error 
of mean) was longer than its F(ab')2 (14.16 +0.65), which 
was longer than the clearance of Feb (8.7 +1.39) 
(P<0.005). IgM FT166 cleared quite rapidly in these ex- 
periments, with a terminal phase blood tlA comparable to 
F(ab')2 (12.6 + 1.20), but slower than Fab (P<0.05). De- 
creasing blood concentrations were generally fitted by bi 
or triexponential equations. Blood samples were not col- 
lected beyond 24 h from the rats given UPC-10 i.p., and 
the terminal phase blood tV2 could not be determined. 
The time course of radioantibody concentration in the 
peritoneal cavity following i.p. injection is shown graphi- 
cally in Fig. 2. These profiles are quite similar to one an- 
other in that there was little overall drop in i.p. antibody 
concentration seen, except after 15 h when only a few sam- 
ples could be obtained from normal animals. Higher, more 
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+ F(ab')2 bid IV | 
1 ~ ~ -,,- IQM bld p iv / 
.01 ~ 
.001 
0 20 40 60 80 100 120 14 
Hours post i.v. injection 
Fig. 1. Clearance of murine antibodies and fragments from the rat blood stream following i.v. injection (mean of 3-5 animals +__ standard 
error of mean (SEM) shown, 225.28S Feb, F(ab')z and intact, as well as FT166 IgM). Note fast initial clearance and slower later phase 
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Fig. 2. Clearance of the same reagents as in Fig. 1, as well as BA-1 IgM and UPC-10 IgG2a, following i.p. administration to adult rats. 
Note the relatively slow decline. Mean % kg injected dose/g + SEM for 3-5 animals is plotted. Peritoneal fluid was generally resorbed 
sufficiently by 9-15 h into the study so that peritoneal fluid sampling became impossible, thus only limited peritoneal fluid data are 
available beyond these times 
prolonged levels of activity were achieved i.p., as com- 
pared with blood levels, following i.p. delivery. The t½ for 
clearance from the peritoneal cavity was longer than the 
measured t½ of clearance from the blood, but due to the 
difficulty in obtaining reliable peritoneal fluid values be- 
yond 10-15 h, it was difficult to determine an exact tlA for 
peritoneal clearance. In fact, in some animals, peritoneal 
fluid radioantibody levels rose during the period of obser- 
vation presumedly related to faster fluid than protein ab- 
sorption. The measured blood t½s immediately after i.v. 
injection were: 1.95, 3, 6.4, and 1.2 h for FT166 IgM, 
F(ab')2 , IgG 225.28S, and 225.28S Fab respectively (all 
phase tV2), which were shorter than the tl½s for peritoneal 
fluid clearance. These differences in clearance rates be- 
tween i.p. levels and blood levels soon after injection ap- 
peared to be the major determinants of the Rd advantage to 
the peritoneal cavity. In selected instances, blood samples 
1 or more days after i.p. antibody injection showed the cir- 
culating antibody to be identical to the species injected i.p. 
using SDS gels. 
The relative concentrations of antibody radioactivity 
in peritoneal fluid, compared with blood, following the 
i.p. injection route are shown in Fig. 3a-f, where a higher 
level of radioantibody activity was seen in the peritoneal 
cavity than in the blood at all times during which fluid 
could be reliably sampled following i.p. antibody injec- 
tion. In occasional instances where peritoneal fluid could 
be obtained 24 h or more after injection the i.p. fluid levels 
had dropped to near blood levels indicating that the i.p. 
delivery advantage had largely disappeared 24 h after in- 
jection. In Fig. 3, the mean level of radioantibody in the 
blood and peritoneal fluid following i.v. injection of the 
same antibody preparation in similar animal groups is 
plotted. The radioantibody levels in the peritoneal fluid 
following i.p. delivery were also generally higher than 
maximal levels achieved in the blood following i.v. deliv- 
ery of the same amount of radioantibody. In addition, the 
AUC for i.p. antibody administration to the peritoneum 
was visibly greater than that of blood following i.v. deliv- 
ery in the time peritoneal fluid could be sampled. By con- 
trast, radioantibody levels in the peritoneal cavity follow- 
ing i.v. delivery, and blood levels following i.p. delivery 
were both quite low in the first 10 h after injection. In the 
first 9 h following injection, 50-110 times more antibody 
reached the peritoneal cavity (for the same blood level) 
following i.p. than following i.v. administration (Rd2). The 
mean Rd advantage expressed in a variety of ways for 
each antibody or fragment is listed in Table 1. Note that a 
substantial Rd advantage existed for each reagent, when 
assessed in the first 9 h after i.p. injection (Rd 0-9/0-9). 
The Rd (0-9/0-9) or the level of i.p. antibody concen- 
tration over time (AUC i.p.) to the peritoneal cavity divid- 
ed by systemic levels (AUC blood) was significantly ele- 
vated (>  1) for all antibodies and fragments, but was most 
elevated for FT166 IgM [Rd (0-9/0-9) = 27.16 _+3.1]. 
This Rd (0-9/0-9) for IgM FT166 was significantly higher 
than for 225.28S Fab (13.63 _+0.98) (P<0.01), which was 
higher than 225.28S F(ab')2 (10.04 _+ 0.72, P<  0.025), which 
in turn was higher than 225.28S IgG (Rd = 7.85 _+0.71) 
(P<0.05). The BA-1 IgM had a lower 0-10 h Rd than the 
FT166 at (9.15 _+3.01). The Rd for UPC-10 was nearly 
identical to that for the 225.28S (6.2 _+ 1.09). Peritoneal 
fluid was frequently difficult to collect beyond 9-10 h after 
injection in normal rats due to resorption, but it was ap- 
parent that the Rd over 15 h was less than over 9-10 h 
(where samples were available, P<0.005), largely due to 
rising blood antibody levels at this time. 
While the Rd (0-9/0-9) was measurable for each rea- 
gent, the more pharmacokinetically correct approach to 
Rd calculation is to integrate the AUC (t = 0 to infinity) 
for peritoneal fluid following i.p. delivery, and to divide 
this by the similar AUC (t = 0 to infinity) for blood. This 
approach was, unfortunately, not feasible for the the peri- 
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Fig. 3 a-f. (a) Clearance of intact IgG2a, 
225.28S; (b) F(ab')2 , 225.28S; (e) Fab, 225.28S; 
(d) IgM, FT166; (e) IgG2a, UPC-10; and (f) 
IgM, BA-1 from the blood and from the perito- 
neal cavity following i.p. (a-f) and i.v. (a-d) de- 
livery of equal amounts of radioantibody. The 
mean of 3-5 animals + SEM is plotted. Note 
that in all instances the highest levels were 
achieved and maintained longest in the peritone- 
al cavity following i.p. toneal administration, 
and that the lowest levels seen were those of ra- 
dioantibody reaching peritoneal fluid following 
i.v. delivery. Note that beyond 10-15 h, perito- 
neal fluid was difficult to reliably obtain, but 
when it was obtained its level of activity follow- 
ing i.p. delivery approached the blood level 
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levels 9-15 h after injection and the fact that in several in- 
stances, a downslope was not seen in the i.p. radioanti- 
body activity in the time observed (making it impossible to 
extrapolate i.p. levels to infinity). For this reasons, it was 
necessary to express Rd to infinity as the measured AUC 
i.p. from 0-9 h and then assume that i.p. antibody levels 
fell immediately to zero. Terminal blood tl/2s were easily 
estimated, however, and the AUC zero to infinity for 
blood could be determined. Thus, the (Rd 0-9/oo) was a 
clear underestimate of Rd, but did allow for another 
means of comparison among the antibodies. These data 
showed the Rd (0-9/00) of Fab of 225 and the IgM FT166 
to be statistically comparable, while the intact IgG, 
225.288; IgM BA-1, and the F(ab')2 of 225.288 were similar 
to one another and significantly (>  95% chance) less than 
the Rd 0-9/oo Fab of 225.288 and FT166. The terminal 
phase blood tl/z of the animals given UPC-10 was not de- 
termined in these studies and no Rd zero to infinity can be 
expressed. It is of interest that by this overly conservative 
measurement, no definite Rd advantage was seen to the 
peritoneal cavity for IgG (225.288) or BA-1 (i.e., Rd 
0-9/oo < 1). As can be seen in Fig. 3a and in Fig. 4a, for 
intact antibody, since blood levels were comparable from 
15 h on, and i.p. levels were greater after i.p. than i.v. de- 
livery a Rd advantage for intact IgG must be present, but 
is not apparent due to the conservative estimation ap- 
proach used when Rd 0-9/eo is used. Absorption rate con- 
stants from the peritoneal cavity were statistically equiva- 
lent among the antibodies and fragments used (Table 2), 
and the Rd was most dependent on the systemic clearance 
rate of the antibody or fragment used. 
Tissue distributions of the four radiolabeled antibodies 
and fragments in normal rats sacrificed at 5-7 days after 
injection, are shown in Table 3. The antibodies used had 
no known binding to rat tissues, and resulted in relatively 
similar tissue levels independent of delivery route at these 
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late times, though with FT166 IgM the i.p. route tended to 
give somewhat lower systemic antibody levels than the i.v. 
route. In all cases, the diaphragm maintained significantly 
higher levels of radioactivity following i.p. delivery than 
the levels in that tissue following i.v. administered anti- 
body (P< 0.001). Other than the diaphragm, the similarity 
in tissue uptake for extraabdominal tissues at late times 
was not unexpected, due to the similarity in blood levels 
achieved by the i.p. or i.v. routes for each radioantibody 
(Fig. 4 a-d) at 15 h and later following injection. It is obvi- 
ous in these normal animals that systemic exposure to ra- 
diolabeled antibody, at later times after injection, was 
quite comparable following the i.p. and i.v. delivery routes. 
Tumor bearing animals 
While normal rats are a useful system to evaluate the clear- 
ance of antibodies and fragments from the peritoneal cavi- 
ty, it is important to determine if the pharmacokinetic dif- 
ferences for nonspecific antibody between i.p. and i.v. de- 
livery extend to the behavior of specific antibody in ani- 
mals with antigen-positive i.p. tumor. For this reason, we 
evaluated the delivery to blood and tumor of radiolabeled 
tumor-specific and nonspecific antibodies following i.p. or 
i.v. injection into normal BALB/c mice, nude mice with- 
out tumors, and nude mice with i.p. ovarian tumors. 
Figure 5 a-d  demonstrates the gamma scan appearance 
of groups of normal nude mice and HTB77 IP3 tumor- 
bearing mice following i.p. or i.v. injection of 131I 5G6.4, 
specific antibody, at 4 h after injection (a = normal nude 
mice after i.p. delivery, b = normal nude mice after i.v. 
delivery, c = IP3 tumor-positive mice after i.p. delivery, 
and d -- IP3 tumor-positive after i.v. delivery). Note that 
in mice given 5G6.4 i.p., there was far more whole body 
activity in the group without tumors (Sa) than in group-5c, 
with tumor, indicating faster egress from the peritoneal 
cavity to the blood. In fact, the normal nude mice with i.p. 
antibody delivery (5a) looked very similar at 4 h to the 
normal mice with i.v. antibody delivery (Sb) and the tu- 
mor-bearing mice after i.v. delivery (5d). Only the tumor- 
bearing animals after i.p. injection had high level i.p. anti- 
body retention (5c). In parallel experiments, this slower 
egress was demonstrated for specific antibody 5G6.4 and 
for nonspecific antibody UPC-10 given i.p. to normal and 
tumor-bearing animals by blood sampling at several times 
points (Fig. 6a). The blood levels of antibody in the 
HTB77 IP3 tumor-bearing animals rose more slowly, and 
peaked later than in the normal animals (Fig. 6a and b). 
The absorption rate constants for UPC-10 or 5G6.4 in tu- 
mor-bearing mice were significantly less than for normals 
(Table 6, P<  0.005). There was no significant difference 
between absorption rate constants for 5G6.4 or UPC- 
l0 (Table 6). Nontarget organ tissue levels of radioactivity 
per gram were similar at sacrifice 3 days after antibody in- 
jection in normal and tumor-bearing animals (Fig. 7). 
Following i.p. or i.v. injection of 125I 5G6.4 in animals 
with i.p. foci of human ovarian cancer HTB77 IP3, there 
was greater absolute tumor uptake following the i.p. route 
of delivery than the i.v. route when examined 4 h after an- 
tibody injection (Fig. 8a and Table 4). Table 4 illustrates 
that antibody uptake was clearly higher in tumor after i.p. 
than i.v. delivery (P< 0.025), while uptake in nontarget tis- 
sues was significantly less in the first 24 h following i.p. de- 
livery. While tumor uptakes were equivalent at 24-120 h, 
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Fig. 4 a-d. (a) Blood levels of intact 225.28S IgG; (5) F(ab')2; (e) Fab and (d) IgM, FT166 following the i.v. or i.p. injection of equal 
amounts of  radiolabeled antibodies. Note that after approximately 18-24 h, the i.p. and i.v. routes of administration resulted in highly 
comparable blood levels 
Table 2. Absorption rate constants from the peritoneal cavity in 
normal rats 
Antibody Absorption rate constant ± SEM (h-]) 
Intact 225.28S 0.098 ± 0.027 
F(ab'): 225.28S 0.118 _+ 0.017 
Fab 225.28S 0.153 _ 0.022 
lgM FT166 0.157_+ 0.055 
IgM BA-I 0.141 ±0.028 
Note: There was no statistically significant difference among the 
mean absorption rate constant for the above reagents 
ing  i.p. than  i.v. de l ivery  Of an t i body  (Fig. 8b). Overa l l  tu- 
m o r / n o n t u r n o r  rat ios were  3 -6  t imes  h igher  at 4 h after  i.p. 
in jec t ion  than  after  i.v. del ivery.  W h e n  la ter  t imes  were  ex- 
amined ,  such as 48 and  120 h (Fig. 8c and  d), the advan -  
tage  o f  i.p. de l ivery  had  d i s appea red  and  up takes  in essen- 
t ial ly all t issues inc lud ing  the  i.p. tumors ,  were  c o m p a r a b l e  
by the  i.p. and  i.v. de l ivery  routes  ( for  the in tac t  IgG).  Tha t  
the  t u m o r  up take  o f  5G6.4 an t i body  was due  to an t ibody  
specif ici ty was a p p a r e n t  in the  dua l - labe l  studies wi th  1311 
5G6.4 with  co in jec t ion  o f  125I U P C - 1 0  i.p. (Table  5). These  
b iod i s t r ibu t ion  f indings  subs tan t ia ted  the scan f indings  
shown in Fig. 5 a -d .  
Table 3. Mean tissue levels of antibodies or fragments at sacrifice 
IgG F(ab')2 Fab IgM a (FT166) 
i.p. i.v. i.p. i.v. i.p. i.v. i.p. i.v. 
Liver 0.0456 0.0390 0.0066 0.0068 0.0062 0.0155 0.0394 0.0196 
___ 0.0026 ± 0.0028 ___ 0.0030 ___ 0.0054 ___ 0.00090 + 0.0036 ± 0.0208 ± 0.0164 
Kidney 0.1167 0.1011 0.0078 0.0054 0.1158 0.1637 0.1462 0.0454 
+__ 0.0073 ± 0.0091 ___ 0.0012 + 0.0025 ± 0.0275 ± 0.0272 + 0.0784 --- 0.0034 
Heart ND ND ND ND 0.0010 0.0014 0.0017 ND 
+ 0.0001 ± 0.0002 ± 0.0005 
Lung 0.2470 0.2580 0.0100 0.0089 0.0021 0.0025 0.0032 0.0010 
± 0.0069 ± 0.025 ± 0.0027 ± 0.0041 + 0.00025 + 0.0003 +__ 0.0010 + 0.0004 
Diaphragmatic 0.0689 0.0276 0.0047 0.0009 0.0113 0.0010 0.0711 0.0013 
muscle* +_ 0.0078 _ 0.0029 ± 0.0030 ± 0.0004 ___ 0.0016 ± 0.0001 ± 0.0350 ± 0.0001 
Skeletal 0.0177 0.0158 0.0009 0.0007 0.0006 0.0008 back- 0.0052 
muscle ± 0.0020 ± 0.0018 ___ 0.0002 ___ 0.0004 + 0.0002 ± 0.0003 ground ± 0.0053 
Data shown are means of 3 -5  animals, and represent time corrected % kg/dose per g at 5 days after injection. 
a 7 days after injection 
* Diaphragmatic muscle radioantibody levels were significantly greater following i.p. delivery (P <0.001) than i.v. delivery for all anti- 
bodies 
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Fig. 5 a-d. Gamma scans 4 h following i.v. and i.p. administration of 13ll 5G6.4 to groups of normal or HTB77 IP3 tumor-bearing nude 
mice. Mice are prone with heads at bottom of figures. (a) Normal, i.p. antibody delivery; (b) normal i.v. antibody delivery; (e) IP3 tumor, 
i.p. antibody delivery; (d) IP3 tumor, i.v. antibody delivery. Note fast egress of antibody from the peritoneal cavity in group-a and slower 
egress in group-c 
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Fig. 6 a-b. The appearance of (a) 5G6.4 (tumor-specific) and (b) UPC-10 (nonspecific) IgG2aks in the blood following i.p. administration 
to tumor-bearing animals is shown. Note the higher early blood levels in the normal animals, compatible with their considerably higher 
absorption rate constants than tumor-bearing animals (Table 6) 
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Table 6. Absorption rate constants (h-~) 
5G6.4 
Tumor (IP3) 0.1173 + 0.0387 (SD) 
Normal 0.8396 ± 0.2370 (SD) a 
UPC-IO 
Tumor (IP3) 0.1134 ± 0.0660 (SD) 
Normal 0.8888 ± 0.7043 (SD) ~ 
Tumor < normal with P < 0.005 
a No difference was seen between 5G6.4 and UPC-10 absorption 
rate constants 
Discussion 
The concept of regional delivery therapy for diseases limit- 
ed to a particular area of the body is compelling [7]. Our 
study has demonstrated considerable Rd advantage (Rd 
0-9/0-9),  for all classes and fragments of Igs used in anti- 
body imaging trials to date, and a particularly high Rd 
0 - 9 / ~  for Fab and the FT166 IgM. These data from nor- 
mal rats showed that the Rd advantages were elevated in 
the first 15 h after i.p. injection of the antibody, and fell 
after this, indicating that this delivery route would be ex- 
pected to be superior to the i.v. route for i.p. disease foci. 
Intact IgG, the obvious first choice for i.p. delivery, has 
pharmacokinetic properties that suggest it will be less opti- 
mal for i.p. delivery than its fragments or some IgMs due 
to its slower clearance from the bloodstream. Despite these 
pharmacokinetic problems, even intact specific IgG did 
show an early Rd advantage in i.p. tumors following i.p. 
delivery, as compared with i.v. delivery. 
Although reliably obtaining peritoneal fluid samples 
from normal rats at later time points was difficult, it ap- 
pears, where fluid could be obtained, that peritoneal fluid 
and blood radioantibody levels began to approach one an- 
other for all reagents given i.p., and that by 24 h the blood 
levels following i.p. or i.v. delivery were nearly identical 
(Fig. 4 a-d). This indicates that large doses of any radio- 
labeled antibody given i.p. may potentially result in sys- 
temic toxicity, as the peritoneal membrane does not pre- 
vent systemic exposure, but only delays it. Our preliminary 
data suggest that the antibody species given i.p. is not al- 
tered by passage from the peritoneal fluid to the blood. 
The somewhat considerably slower clearance of radioan- 
tibody from the peritoneal cavity in i.p. tumor-bearing 
mice versus normal mice (approximately 8-fold) suggested 
that the i.p. tumors may offer some degree of protection to 
systemic exposure, possibly by lymphatic obstruction, but 
in animals with limited to moderate disease burden, anti- 
body does eventually reach the systemic circulation in con- 
siderable quantity. We have recently reported preliminary 
data from normal nude mice indicating that significant 
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Fig. 7 a-b. Uptake of 5G6.4 (a) and UPC-10 (b) antibody to normal organs 72 h after i.p. injection in normal and tumor-bearing animals. 
Note that despite the slower absorption rate constant in the tumor-bearing animals, that normal tissue uptakes have become quite compa- 
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Fig. 8 a-d. HTB77 IP3 tumor and normal tissue uptakes of 125I 5G6.4 at 4 h (a), 24 h (b), 48 h (e), and 120 h (d) following i.p. or i.v. 
injection. Note the higher absolute tumor uptake at 4 h after injection by the i.p. route, and the higher relative uptake to tumor extending 
to 24 h for the i.p. route. At 48 h and later, the uptake of antibody was comparable between i.p. and i.v. delivery routes 
Table 4. Data at 4 h (HTB77 IP3 animals) 
i.p. 5G6.4 Pvalue i.v. 5G6.4 
(n = 6) (n = 7) 
Tumor a 0 . 1 8 3 _ + 0 . 0 3 3  <0.025 0.085_+0.018 
Livera 0.044 _+ 0.008 < 0.025 0.078 _+ 0.01 
Blood" 0.083+0.019 <0.1 0.18 +0.052 
Muscle" 0.011 -+ 0.001 NS 0.011 -+ 0.001 
Tumor/blood 2.369-+0.699 <0.025 0.73 +0.332 
Tumor/muscle 16.968-+3.725 <0.025 8.035+1.318 
Tumor/liver 5.19 -+ 1.371 <0.025 1.074_+0.162 
Values as % kg injected dose/g _+ SEM 
is given i.p. and that  this toxici ty is comparable  between 
the i.p. and i.v. delivery routes [28]. The pharmacokine t ic  
ra t ionale  demonst ra ted  in these animal  studies also applies 
to specific an t ibody  delivery in the i.p. human ovar ian car- 
c inoma xenograft  tumor  system using HTB77 IP3 cells. In 
this model  system, the del ivery of  the 5G6.4 an t ibody  to 
solid i.p. tumor  foci 4 h after i. p. injection was 50% more 
than that of  the same an t ibody  given i.v., with t u m o r / n o n -  
tumor  ratios up to 6 times the i.v. route (Table 4 and Fig. 
8a). For  free individual  tumor  cells in the per i toneal  cavi- 
ty, the i.p. del ivery advantage  (Rd2) approached  100-fold 
in the first 9 h for the same dose of  an t ibody  given by the 
i.p. as compared  to the i.v. route. Thus one would expect 
individual  tumor  cells that are not  vascularized to have an 
even greater Rd advantage  (approaching  Rd2) than the sol- 
id i.p. tumor  foci repor ted  in Fig. 8 a - d  and Table 4. 
F rom these data,  the Rd 0-9 /oo  for the Fab of  225.28S 
and the FT166 IgM were noted to be super ior  to those of  
the other ant ibodies  and fragments.  The BA-1 IgM did not  
have the same high Rd as the FT166, however.  Thus it does 
not  appear  general ly t r u e t h a t  all IgMs are greatly superior  
to IgGs as regards Rd. The observat ion that  225.28S Fab 
had  a high Rd is of  considerable  interest and was appar-  
ently related to the considerably  faster systemic clearance 
of  Fab  than, for example,  intact  ]gG 225.28S. The essen- 
t ial ly identical  absorpt ion  rate constants  from the perito- 
neal  cavity for the varying classes and fragments of  Ig was 
somewhat  surprising, based on the repor ted  rela t ionship 
between molecular  weight and  per i toneal  clearance shown 
for smaller  molecules given i.p. [7]. It should be noted that  
the heaviest molecule  examined in this series was insulin, 
with a molecular  weight of  approximate ly  5,000 [7]. Inter- 
estingly, intact IgG (either 225.28S or UPC-10), the only 
an t ibody  class used to date repor ted  used in humans  for 
i.p. therapy,  had the lowest Rd  of  any of  the ant ibody 
moieties tested. In  fact, in examining the clearance rates 
from the per i toneal  cavity (Fig. 2), and the absorpt ion  rate 
constants  (Table 2), it is apparen t  that  the systemic, not  the 
peri toneal ,  clearance differences were the main  determi- 
nants  of  the differences in Rd  among an t ibody  classes and 
fragments. 
The faster systemic clearance of  Fab can be mimicked  
to improve  the Rd of  intact IgG, as has been shown in ex- 
per iments  in which we have accelerated the systemic clear- 
Table 5. Specificity of i.p. delivery, data at 24 h 
5G6.4 P UPC-10 
Tumor a 0.091 ± 0.006 < 0.005 0.05524 _+ 0.005 
Liver" 0.03 +0.012 NS 0.03 +0.002 
Blood~ 0.023_+0.005 <0.025 0.09 _+0.018 
Muscle a 0.011 +0.001 <0.025 0.024 +0.003 
Tumor/liver 4.419+_ 1.261 <0.05 1.812 -+0.129 
Tumor/blood 4.751± 1.215 <0.01 0.679 +__0.124 
Tumor/muscle 9.067_+2.056 <0.025 2.526 ___0.53 
a Values as mean % kg injected dose/g + SEM following i.p. 
dual-label coinjection of specific (T3~I 5G6.4) and nonspecific 
(125I UPC-10) antibody to nude mice with HTB77 IP3 tumor 
located i.p. 
~311 5G6.4 bound approximately 45% of input counts, and UPC-10 
< 1% to target cells in a 1-h binding assay 
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ance of iodinated intact IgG by using a polyclonal anti- 
mouse antibody given systemically [21]. This approach, 
which presumably forms radioactive immune complexes 
which are then catabolized by the liver, considerably di- 
minishes systemic exposure to radioantibody without mea- 
sureable impact on i.p. exposure. This approach takes ad- 
vantage of the fact that little of the polyclonal anti-mouse 
antibody given systemically will reach the peritoneal cavi- 
ty, and the fact that clearance from the peritoneal cavity 
does not appear to be increased by this approach. Alterna- 
tively, we have recently reported preliminary data in i.p. 
ovarian carcinomatosis that relative tumor exposure can 
be enhanced by lavage of the peritoneal cavity several 
hours after antibody injection [28]. 
In our opinion, the Rd may be most relevant in terms 
of the incrementally larger dose that may be given region- 
ally, as it most clearly reflects the relative systemic expo- 
sure expected for a given i.p. dose. The Rd2, a term to de- 
scribe the improvement in delivery to the peritoneal space 
by the i.p. route as compared to peritoneal delivery by the 
i.v. route, is analogous to the Rd used by Collins and De- 
drick to describe the improvement in tumor exposure to 
chemotherapeutic agents by the intraarterial delivery 
route, as compared to the i.v. (systemic) route [6]. In evalu- 
ating this term, F(ab')2 225.28, 225.28S IgG, and FT166 
IgM gave comparable, approximately 100-fold, improve- 
ments in delivery to the peritoneal cavity by the i.p. route 
as compared with the i.v. route, (Rd 2 0-9 h) with the Fab 
producing a slightly lesser, but still marked improvement 
(Rd2 0-9 h = approximately 60). 
Tissue levels of antibody activity in the mouse studies 
indicated that the i.p. delivery route resulted in lower sys- 
temic exposure to radiolabeled antibody early on (as 
judged by blood levels), but later, the nontarget tissue lev- 
els were quite similar to those achieved following i.v. deliv- 
ery. The radioantibody levels in the diaphragm were al- 
ways higher following i.p. delivery than those achieved fol- 
lowing i.v. delivery at 5-7 days following injection. This 
higher diaphragmatic uptake was presumably due to the 
intimate contact of the antibody and hemidiaphragm dur- 
ing antibody egress from the peritoneal cavity (possibly 
through lymphatics in the diaphragm) and suggests that 
the entire peritoneal surface may have high exposure at 
these later time points, even if no fluid is available for 
sampling. The comparable later systemic exposure levels 
for the various antibodies given i.v. or i.p. in normal rats, 
indicate that the i.p. route, although delivering more radio- 
active antibody to the peritoneal space, does not elimi- 
nate, but does delay systemic exposure, and that systemic 
toxicity certainly may result following i.p. radioimmuno- 
therapy [30]. 
While the pharmacokinetic data in normal rats are of 
interest, of greater practical relevance is that this study al- 
so showed that the high i.p. Rd advantage seen with mono- 
clonal antibodies can be translated successfully into high- 
er uptakes of specific antibody into i.p. ovarian carcinoma 
tumor foci than following i.v. administration (at early time 
points after injection). This advantage disappeared at later 
times, which probably explains our preliminary unsuccess- 
ful attempts to detect enhanced delivery to i.p. as com- 
pared to extraperitoneal ovarian carcinoma xenographs 
after i.p. radioantibody delivery when the tumors were ex- 
amined at 7 days after monoclonal antibody injection [22]. 
Of  note is that the absorption rate constant for IgG in nor- 
real mice was 7-8 times larger than in tumor-bearing mice, 
suggesting the tumor may make regional delivery more ra- 
tional, though not eliminating systemic exposure (Fig. 7a 
and b). That these pharmacokinetic and localization data 
following i.p. antibody delivery are relevant to radioim- 
munotherapy is indicated by our recent demonstration in 
an i.p. human colon carcinoma xenograft system that i.p. 
radioimmunotherapy with the 131I 5G6.4 monoclonal is 
significantly superior to the i.v. delivery route [29]. 
In conclusion, the i.p. route of radioantibody delivery 
offers a significant enhancement in antibody delivery to 
the peritoneal space in normal and tumor-bearing animals 
as compared to the i.v. route. Fab, F(ab')2 , and some IgMs 
appear pharmacokinetically superior to intact lgGs for i.p. 
delivery with the Fab being most superior pharmacokine- 
tically. Naturally, evaluation of these and other antibody 
fragments in animals with i.p. tumor will be of additional 
interest as well as varying injected protein dose and vol- 
ume. These pharmacokinetic data support the concept that 
the i.p. injection route is a rational means to deliver specif- 
ic monoclonal antibodies to i.p. tumor foci. These data 
should be very useful in planning diagnostic and therapeu- 
tic studies using this delivery route. 
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